altRx review

altRx offers compounded semaglutide and tirzepatide alongside approved-brand GLP-1 listings. The cited compounded product prices are $89 and $149 monthly. The company advertises the same price across doses and includes clinical consultation, medication and shipping without a separate membership fee. Treat that as the current advertised policy, not a guarantee that every future agreement or different product has the same price. Request the full charge, commitment, supply per shipment and renewal schedule before enrollment. A brand listing needs its own quote and should not inherit the compounded product’s bundle price.

The terms distinguish altRx’s nonclinical marketing and support role, OpenLoop’s platform role, and medical services provided through professional practices. The product footer names OpenLoop Healthcare Partners and related practices as the clinical network. A provider evaluates eligibility and may use live or written consultation according to the circumstances and state requirements. An online assessment alone does not establish a clinician-patient relationship or guarantee a prescription. The company advertises broad US access, but a nationwide membership claim does not establish availability of every medication in every state. Confirm the particular treatment, clinician and follow-up arrangements for your location.

The product FAQ lists Red Rock, Health Warehouse and Precision Medicine with contact and location information. These disclosures give you facilities to ask about; they do not independently verify current licenses or identify which pharmacy is assigned to your prescription. Ask for that assignment and verify the dispensing site through its regulator before relying on general quality statements. Shipping estimates also remain estimates: the terms explain possible pharmacy, verification, carrier and weather delays. A delivery range should not be treated as a promise that medication will arrive a fixed number of days after the first assessment.

There is a material cancellation discrepancy. General terms permit cancellation up to forty-eight hours before the monthly processing date, while the separate refund policy requires at least seventy-two hours before the billing date. Ask which agreement controls the actual order and use the earlier deadline while obtaining clarification. The refund policy makes payments final at purchase, including incomplete intake, unused services and multi-month commitments. Provider-initiated medical disqualification has an unused-value calculation after deducting services already rendered, including review, consultations, prescriptions, medication and labs. It should not be described as a guaranteed full refund merely because medicine has not arrived.

Problems with damaged or incorrect medication have a separate replacement process, with prompt reporting and evidence of damage. The policy describes replacement rather than an automatic cash refund. Product storage copy also needs attention: the semaglutide page allows room-temperature use for up to fifty-six days after opening. FDA’s current guidance for multi-dose compounded GLP-1 vials recommends discarding within twenty-eight days after first use even if compounder instructions allow longer. That discrepancy should be resolved with the dispensing pharmacist before using a vial beyond the agency’s recommended period. A branded product’s storage allowance cannot simply be transferred to a compounded vial.

FDA’s cited warning letter criticized labels suggesting altRx was the compounder and claims implying compounded GLP-1s had been clinically proven or evaluated like approved medicines. It is not a closure order or product approval. Current marketing also presents trial-like weight-loss figures while the footer describes self-reported member results; neither establishes the expected result from your specific preparation. Compounded drugs are not FDA-approved. The reviewed sources do not establish a separately priced, currently orderable NAD+, sermorelin or glutathione program, so those homepage categories should not be treated as confirmed treatment offers. Compare the actual prescription pathway and evidence rather than the breadth of the menu.